Clinical Trial Update: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating HWK-007, a PTK7-directed antibody-drug conjugate, for advanced solid tumors; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• HWK-007

Snippet

Sponsor: Whitehawk Therapeutics, Inc. | Conditions: Endometrial Cancer, Ovarian Cancer | Phase 1 | Status: RECRUITING